(Q34571545)

3 August 2017

1 reference

title

Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. (English)

1 reference

3 August 2017

0 references

1 reference

Michael R Jacobs

1

1 reference

3 August 2017

Peter C Appelbaum

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

7

1 reference

3 August 2017

issue

14

1 reference

3 August 2017

page(s)

1957-1966

1 reference

Comparative activity of the topical quinolone OPC-7251 against bacteria associated with acne vulgaris

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Optimal management of acne to prevent scarring and psychological sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Update and future of systemic acne treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Effect of nadifloxacin on atopic dermatitis with methicillin-resistant Staphylococcus aureus in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Treatment of bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Practice guidelines for the diagnosis and management of skin and soft-tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

21 January 2018

Acne: topical treatment

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

21 January 2018

Acne: systemic treatment

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Guidelines for treating acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

A review of the use of combination therapies for the treatment of acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

The treatment of acne: the role of combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

In vitro activity of the new quinolone WCK 771 against staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Quinolones in 2005: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Fusidic acid resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Fusidic-acid use and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Fusidic acid resistance in community isolates of methicillin-susceptible Staphylococcus aureus and fusidic acid prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Antimicrobial resistance of Staphylococcus aureus isolated from impetigo patients between 1994 and 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Observations on high levels of fusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Resistance of Staphylococcus aureus to fusidic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Fusidic acid resistance in Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

Fluoroquinolone treatment of skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.14.1957

10.1517/14656566.7.14.1957

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference